<i id='62E417C2B5'><strike id='62E417C2B5'><tt id='62E417C2B5'><pre id='62E417C2B5'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Moonlake's readout produced a cash windfall. Risks remain 
Hospitals, health systems can help patients avoid medical debt 
Dobbs anniversary: the lost opportunity of abortion as health care 
The Jan. 6 committee previously recommended Trump be criminally charged. Here's why 
Medicare details structure of new drug price negotiation program 
Senators start work on Medicare physician payment reform 
Hepatitis C has a cure — but many Americans still lack access to it 
Bryan Kohberger seeks indictment dismissal in Idaho college killings case 
Medical leaders decry Supreme Court decision on affirmative action 
Medicare threatens to cut off funding for HCA's Mission hospital 
Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen 
Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms 
Apple is now the first public company to be valued at $3 trillion 
How digital tools helped lower hypertension in marginalized patients 
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
